WallStreetZenWallStreetZen

NYSEMKT: CANF
Can Fite Biopharma Ltd Earnings & Revenue

CANF past revenue growth

How has CANF's revenue growth performed historically?
Company
-8.27%
Industry
148.64%
Market
17.33%
CANF's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CANF's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CANF's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CANF earnings and revenue history

Current Revenue
$743.0k
Current Earnings
-$7.6M
Current Profit Margin
-1,027.5%

CANF Return on Equity

Current Company
-142.5%
Current Industry
-63.5%
Current Market
188%
CANF's Return on Equity (-142.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CANF announces earnings.

CANF Return on Assets

Current Company
-79.2%
Current Industry
2.9%
CANF is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CANF Return on Capital Employed

Current Company
-95.8%
Current Industry
19.5%
CANF has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CANF vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CANF$743.00k-$7.53M-$7.63M-27.92%N/A
HEPA$0.00-$49.26M-$48.93MN/AN/A
ASLN$12.00M-$39.41M-$44.22M+41.42%N/A
CYCN$0.00-$5.62M-$5.26M-100.00%N/A
VIRI$0.00-$5.30M-$5.30MN/AN/A

Can Fite Biopharma Earnings & Revenue FAQ

What were CANF's earnings last quarter?

Can Fite Biopharma (NYSEMKT: CANF) reported Q4 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Can Fite Biopharma earnings for the quarter were N/A. In the same quarter last year, Can Fite Biopharma's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Can Fite Biopharma stock.

What was CANF's earnings growth in the past year?

As of Q2 2024, Can Fite Biopharma's earnings has grown year over year. Can Fite Biopharma's earnings in the past year totalled -$7.63 million.

What was CANF's revenue last quarter?

Can Fite Biopharma (NYSEMKT: CANF) reported Q4 2023 revenue of N/A up N/A year over year. In the same quarter last year, Can Fite Biopharma's revenue was N/A.

What was CANF's revenue growth in the past year?

As of Q2 2024, Can Fite Biopharma's revenue has grown -8.27% year over year. This is 156.91 percentage points lower than the US Biotechnology industry revenue growth rate of 148.64%. Can Fite Biopharma's revenue in the past year totalled $743.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.